Blockade of Renin-Angiotensin System Attenuates Advanced Glycation End Products-Mediated Signaling Pathways

Abstract

Aim: Advanced glycation end products (AGE) and a receptor for AGE (RAGE) play a key role in diabetic vascular complications. Matrix metalloproteinases (MMPs) and apoptosis contribute to plaque instability. The renin-angiotensin system (RAS) is crucial for NADPH oxidase-dependent redox signaling pathways in the vascular wall. We investigated the effects of RAS blockade on AGE-triggered signaling pathways and its downstream events, including MMP-9 and apoptosis. Methods: We used cultured rabbit aortic smooth muscle cells (SMCs), which were stimulated with AGE in the presence or absence of temocaprilat or olmesartan. Results: Angiotensin converting enzyme (ACE) mRNA levels were increased 4 to 6 hours after adding AGE. AGE induced Rac1 and p47 phox membrane translocation, reactive oxygen species (ROS) generation and NF-B phosphorylation within 15 minutes, and various molecular expressions after 18 hours, which were attenuated by RAS blockade by temocaprilat or olmesartan. AGE-induced RAGE expression, as well as other molecules, including membrane type 1-MMP (MT1-MMP), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1), was NADPH oxidase signaling-dependent and blunted by temocaprilat and olmesartan. The parameters of plaque instability, including MMP-9 expression and activity, and apoptosis were up-regulated by AGE, which was markedly attenuated by temocaprilat or olmesartan. Using isolated human monocyte culture, AGE-induced ROS generation and molecular expression were also attenuated by RAS blockade.Conclusion: The present study shows that AGE-triggered NADPH oxidase signaling pathways, including MMP-9 and apoptosis, were attenuated by RAS blockade, which may be an attractive strategy for treating plaque instability in diabetic vascular complications. J Atheroscler Thromb, 2010; 17:590-600.

Angiotensin II Receptor Blocker Improves Tumor Necrosis Factor-a-Induced Cytotoxicity via Antioxidative Effect in Human Glomerular Endothelial Cells

“…RNH-6270 showed no ef- fect on the electron paramagnetic resonance signals of the DMPO/superoxide spin adduct [14]. Kamioka et al [21] also reported that olmesartan inhibited ROS production by advanced glycation end products via inhibition of NADPH oxidase activity. TNF-α-induced ROS production is also mediated by NADPH oxidase acitivation [22].…”

Dietary Advanced Glycation End Products and Their Role in Health and Disease

“…Several currently available pharmacologic agents may regulate esRAGE or sRAGE. Inhibitors of angiotensin-converting enzyme (ACE) increase renal expression of sRAGE in rats, and this is associated with decreases in the expression of RAGE (28). ACE inhibition in diabetic rats and in humans with type 1 diabetes significantly increases sRAGE concentrations (28).…”

Luteolin Protects HUVECs from TNF-α-induced Oxidative Stress and Inflammation via its Effects on the Nox4/ROS-NF-κB and MAPK Pathways

“…Indeed, clinical drugs inhibiting the Nox4/ROS-NF-κB pathway can be used in the treatment and/or prevention of atherosclerosis. For example, angiotensin-converting enzyme inhibitors, such as temocaprilat, or angiotensin Ⅱ receptor antagonists, such as olmesartan, not only inhibit the NADPH oxidase activity, including the p22phox expression, but also NF-κB activation, which induces the generation of ROS 41,42) . Statins also inhibit the NAPDH oxidase activity 43,44) and the activation of various related downstream signaling pathways, including that of p38 and ERK1/2, in order to produce anti-atherosclerotic effects 14,45) .…”